Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2 shedding and genital lesion rates. Upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback